Reviewer's report

Title: Renal Sympathetic Denervation Versus Antiarrhythmic Drugs for Drug-Resistant Hypertension and Symptomatic Atrial Fibrillation (RSDforAF Trial): study protocol for a randomized controlled trial

Version: 2 Date: 21 May 2013

Reviewer: Bertram Pitt

Reviewer's report:

The authors have responded to most of my questions, although I continue to believe that their choice of both paroxysmal and persistent AF as inclusion criteria may make interpretation difficult. I believe that the paper is now acceptable with a lower-modest priority.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

Potential conflicts of interest:
consultant pfizer, bayer, takeda, relypsa*, scParmaceuticals*, aurasense*, gambro, amorcyte, mesoblast, cytopherx
*-stock options